Eton Pharmaceuticals Inc
NASDAQ:ETON
Eton Pharmaceuticals Inc
EPS (Diluted)
Eton Pharmaceuticals Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Eton Pharmaceuticals Inc
NASDAQ:ETON
|
EPS (Diluted)
$0
|
CAGR 3-Years
-23%
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
EPS (Diluted)
$5
|
CAGR 3-Years
-9%
|
CAGR 5-Years
1%
|
CAGR 10-Years
0%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
EPS (Diluted)
-$4
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Pfizer Inc
NYSE:PFE
|
EPS (Diluted)
$1
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
0%
|
|
|
Merck & Co Inc
NYSE:MRK
|
EPS (Diluted)
$6
|
CAGR 3-Years
9%
|
CAGR 5-Years
12%
|
CAGR 10-Years
5%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
EPS (Diluted)
$11
|
CAGR 3-Years
24%
|
CAGR 5-Years
6%
|
CAGR 10-Years
18%
|
|
Eton Pharmaceuticals Inc
Glance View
Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. The company is headquartered in Deer Park, Illinois and currently employs 17 full-time employees. The company went IPO on 2018-11-09. Eton is primarily focused on hospital injectable and pediatric rare disease products. The Company’s Biorphen product is an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. Its Alkindi Sprinkle product is a replacement therapy for pediatric adrenal insufficiency (AI), including congenital adrenal hyperplasia (CAH) in patients from birth to less than 17 years of age. Its product pipeline includes Zonisamide Oral liquid, Topiramate Oral Solution, Cysteine Injection, Dehydrated Alcohol Injection, Ephedrine Injection and Lamotrigine Oral Suspension. The firm's product candidates are primarily focused on two core areas: hospital-based products and pediatric oral liquid products.
See Also
What is Eton Pharmaceuticals Inc's EPS (Diluted)?
EPS (Diluted)
-0.2
USD
Based on the financial report for Dec 31, 2024, Eton Pharmaceuticals Inc's EPS (Diluted) amounts to -0.2 USD.
What is Eton Pharmaceuticals Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
32%
Over the last year, the EPS (Diluted) growth was -275%. The average annual EPS (Diluted) growth rates for Eton Pharmaceuticals Inc have been -23% over the past three years , 32% over the past five years .
You don't have any saved screeners yet